Linfoma de Hodgkin Online (Hodgkin´s Lymphoma)
¨Os linfomas são neoplasias do sistema imunitário com procedência em linfócitos que envolvem os tecidos linfoides com desenvolvimento de massas tumorais. Estão distribuídos em dois grupos principais: linfomas de Hodgkin (LH) e linfomas não Hodgkin. O LH é uma neoplasia linfoproliferativa caracterizada histopatologicamente pela presença de células neoplásicas com variada morfologia denominadas Reed-Sternberg, em meio a infiltrdo de linfócitos pequenos (não-neoplásicos). Geralmente, o paciente tem adenopatia cervical, que pode evoluir com acometimento de outras cadeias. O estadiamento segue o sistema de Ann Arbor. Parte do estadiamento inclui a avaliação da medula óssea, sendo a biópsia mandatória. O linfoma de Hodgkin (LH) é considerado uma doença curável em aproximadamente 75% dos casos. O papel da radioterapia na abordagem do linfoma de Hodgkin é bem definido. O regime quimioterápico mais utilizado é o chamado ABVD, associado ou não a radioterapia para massas originalmente maiores que 10 cm e nos estágios mais iniciais em associação ao esquema ABVD. Para os raros pacientes com doença refratária ou recidivada, existem diversos regimes de salvamento e pode lançar-se mão de quimioterapia de altas doses com resgate de células-tronco autólogas (transplante autólogo) ou até transplante alogênico de células-tronco. São vários os efeitos tardios do tratamento da doença de Hodgkin: leucemias secundárias ao uso de medicamentos quimioterápicos e/ou radioterapia, câncer de mama secundário, a radioterapia do tórax, a doença coronariana precoce, pericardite constrictiva, hipotireoidismo e aumento da incidência de diversos tumores sólidos durante a evolução clínica nos anos subsequentes ao tratamento. ¨
■ Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D A Eichenauer, B M P Aleman, M André et al
Annals of Oncology 2018, vol 29, issue supplement_4: pages iv19-iv 29
https://academic.oup.com/annonc/article/29/Supplement_4/iv19/4999396
■ Imaging features of extranodal involvement in paediatric Hodkin lymphoma
Suzanne Spijkers, Annemieke S. Littooij, Paul D. Humphries et al
Pediatr Radiol. 2019; 49(2): 266–276
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334729/
■ CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interations and xenograft growth
Naike Casagrande, Cinzia Borghese, Lydia Visser et al
Haematologica. 2019 Mar; 104(3): 564–575
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395337/
■ A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
Eric Van Den Neste, Marc André, Thomas Gastinne et al
Haematologica. 2018 May; 103(5): 840–848
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927969/
■ Hodgkin lymphoma: a review and update on recent progress
S Shanbhag, R F Ambinder
CA Cancer J Clin 2018, vol 68 (2): 116-132
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842098/
■ Fluorodeoxyglucose-positron emission tomography staging can replace bone marrow biopsy in Hodgkin’s lymphoma. Results from Brazilian Hodgkin’s Lymphoma Study Group.
Cerci, Juliano Júlio et al.
Hematol., Transfus. Cell Ther., Sept 2018, vol.40, no.3, p.245-249
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792018000300245&lng=en&nrm=iso
■ The role of immune checkpoing inhibitors in classical Hodgkin lymphoma
Nicholas Meti, Khashayar Esfahani, Nathalie A. Johnson
Cancers (Basel) 2018 Jun; 10(6): 204.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025119/
■ Expression of the immune checkpoint receptor TIGIT in Hodgkin´s lymphoma
Wenchao Li, Niclas C. Blessin, Ronald Simon et al
BMC Cancer. 2018; 18: 1209
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280445/
■ Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management
Dennis A. Eichenauer, Andreas Engert
Hematology Am Soc Hematol Educ Program. 2017 Dec 8; 2017(1): 324–328
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142570/
■ What´s new on primary Hodgkin´s lymphoma of the breast? A case report and review of the literature
M Faenza, A Ronchi, A Santoriello et al
Int J Surg Case Rep 2017, vol 38:149-153
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537453/
■ High frequency of primary refractory disease and low progression-free survival rate of Hodgkin’s lymphoma: a decade of experience in a Latin American center
Jaime-Pérez, José Carlos et al.
Rev. Bras. Hematol. Hemoter., Dec 2017, vol.39, no.4, p.325-330
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000400325&lng=en&nrm=iso
■ Hodgkin’s lymphoma in developing countries: can we go further?
Gaiolla, Rafael Dezen.
Rev. Bras. Hematol. Hemoter., Dec 2017, vol.39, no.4, p.299-300
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000400299&lng=en&nrm=iso
■ New agents in relapsed/refractory Hodgkin’s lymphoma
Biasoli, Irene and Spector, Nelson
Rev. Bras. Hematol. Hemoter., Sept 2017, vol.39, no.3, p.193-196
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000300193&lng=en&nrm=iso
■ Everolimus as a single agent in refractory or relapsed Hodgkin’s lymphoma: the Brazilian Named Patient Program Experience.
Rocha, Talita Máira Bueno da Silveira da et al.
Rev. Bras. Hematol. Hemoter., Sept 2017, vol.39, no.3, p.216-222.
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000300216&lng=en&nrm=iso
■ Cutaneous granulomatous reaction as the first manifestation of Hodgkin’s lymphoma
Moreira, Catarina et al.
Rev. Bras. Hematol. Hemoter., Mar 2017, vol.39, no.1, p.70-72
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000100070&lng=en&nrm=iso
■ Hodgkin lymphoma: current status and clinical trial
Catherine S. Diefenbach, Joseph M. Connors, Jonathan W. Friedberg et al
J Natl Cancer Inst. 2017 Apr; 109(4): djw249
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059238/
■ Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkins lymphoma: a systematic review and meta-analysis of randomized clinical trials
Dennis A. Eichenauer, Ingrid Becker, Ina Monsef, et al
Haematologica. 2017 Oct; 102(10): 1748–1757
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622859/
■ Long-term hospitalization rates among 5-years survivor of Hodgkin lymphoma in adolescence or young adulthood: A nationwide cohort study
Kathrine Rugbjerg, Maja Maraldo, Marianne C. Aznar et al
Int J Cancer. 2017 May 15; 140(10): 2232–2245
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396317/
■ Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management
S M Ansell
American Journal of Hematology march 2016
https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.24272
■ Treatment of relapsed and refractory Hodgkin lymphoma
Bastian von Tresckow, Craig Moskowitz
Semin Hematol. 2016 Jul; 53(3): 180–185
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637390/
■ Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients.
Delamain, Marcia Torresan et al.
Rev. Bras. Hematol. Hemoter., Sept 2016, vol.38, no.3, p.247-251
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842016000300247&lng=en&nrm=iso
■ Pediatric Hodgkin lymphoma – biomarkers, drugs, and clinical trials for translational science and medicine
Poonam Nagpal, Mohamed R. Akl, Nehad M. Ayoub et al
Oncotarget. 2016 Oct 11; 7(41): 67551–67573
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341896/
■ Hodgkin lymphoma in the elderly, pregnant, and HIV-infected
Veronika Bachanova, Joseph M. Connors
Semin Hematol. 2016 Jul; 53(3): 203–208
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568247/
■ Evaluation correlates C-reactive protein with advanced stage Hodgkin’s lymphoma and response to treatment in a tertiary university hospital in Brazil.
Rocha, Talita Máira Bueno da Silveira da et al.
Rev. Bras. Hematol. Hemoter., Aug 2015, vol.37, no.4, p.242-246
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842015000400242&lng=en&nrm=iso
■ Outcomes in relapsed Hodgkin’s lymphoma treated with autologous and allogeneic hematopoietic cell transplantation at the Pontificia Universidad Católica de Chile
Ramirez, Pablo et al.
Rev. Bras. Hematol. Hemoter., June 2015, vol.37, no.3, p.184-189
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842015000300184&lng=en&nrm=iso
■ Lymphocyte-predominant Hodgkin´s disease in children: a case study and review of the literature
J R Stier, R J Vasquez
Case Reports in Oncology 2015, Article ID 351431
https://www.hindawi.com/journals/crionm/2015/351431/
■ Fertility in female survivors of Hodgkin’s lymphoma
Biasoli, Irene et al.
Rev. Bras. Hematol. Hemoter., 2012, vol.34, no.1, p.48-53
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842012000100014&lng=en&nrm=iso
■ Hodgkin lymphoma
R Küppers, A Engert, M Hansmann
J Clin Invest 2012, vol 122 (10): 439-3447
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534167/
■ Hodgkin´s lymphoma: a review of neurologic complications
S Grimm, M Chamberlain
Advances in Hematology 2011, Article ID 624578, 7 pages
https://www.hindawi.com/journals/ah/2011/624578/
■ Recent advances in the pathobiology of Hodgkin´s lymphoma: potential impact on diagnostic, predictive, and therapeutic strategies
D Banerjee
Advances in Hematology 2011, Article ID 439456, 19 pages
https://www.hindawi.com/journals/ah/2011/439456/
■ Transplante autólogo de células-tronco em linfoma de Hodgkin: análise de uma opção terapêutica.
Arantes, Adriano de Moraes et al
Einstein (São Paulo), June 2011, vol.9, no.2, p.124-129
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082011000200124&lng=en&nrm=iso&tlng=pt (portuguese)
■ Hodgkin’s disease and pregnancy: case series and proposal for treatment protocol.
Kassab, Carolina et al.
Einstein (São Paulo), June 2011, vol.9, no.2, p.216-219
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082011000200216&lng=en&nrm=iso
■ Linfoma de Hodgkin: aspectos atuais.
Spector, Nelson.
Rev. Bras. Hematol. Hemoter., Ago 2009, vol.31, suppl.2, p.3-6
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842009000800002&lng=pt&nrm=iso
■ Dr Paulo Fernando Leite
Cardiologia/Prevenção Cardiovascular
Estratificação de Risco Cardiovascular
Novo endereço:
Consultório: Rua Padre Rolim 815/sala 815
Tel: 33245518 (Consulta Particular/Unimed)
– Centro Médico Unimed BH/Contagem/Pedro I
Belo Horizonte/MG/Brasil
CRMMG: 7026
Email: pfleite1873@gmail.com